Premium
TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA
Author(s) -
Soumerai J.D.,
Ni A.,
Batlevi C.,
Alperovich A.,
Bantilan K.S.,
Palomba M.,
Gerecitano J.F.,
Noy A.,
Hamlin P.,
Moskowitz C.H.,
Copeland A.R.,
Matasar M.J.,
Drullinsky P.R.,
Hamilton A.,
Horwitz S.M.,
Intlekofer A.M.,
Kumar A.,
Moskowitz A.,
Portlock C.,
Sauter C.,
Straus D.J.,
Caron P.,
Ying Z.,
Smith K.,
Younes A.,
Zelenetz A.D.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_93
Subject(s) - medicine , asymptomatic , follicular lymphoma , relative survival , clinical endpoint , population , stage (stratigraphy) , surrogate endpoint , overall survival , lymphoma , surgery , clinical trial , cancer , cancer registry , paleontology , biology , environmental health